Genetic Variants of Adrenoceptors.

Q1 Pharmacology, Toxicology and Pharmaceutics Handbook of experimental pharmacology Pub Date : 2024-01-01 DOI:10.1007/164_2023_676
Andrea Ahles, Stefan Engelhardt
{"title":"Genetic Variants of Adrenoceptors.","authors":"Andrea Ahles, Stefan Engelhardt","doi":"10.1007/164_2023_676","DOIUrl":null,"url":null,"abstract":"<p><p>Adrenoceptors are class A G-protein-coupled receptors grouped into three families (α<sub>1</sub>-, α<sub>2</sub>-, and β-adrenoceptors), each one including three members. All nine corresponding adrenoceptor genes display genetic variation in their coding and adjacent non-coding genomic region. Coding variants, i.e., nucleotide exchanges within the transcribed and translated receptor sequence, may result in a difference in amino acid sequence thus altering receptor function and signaling. Such variants have been intensely studied in vitro in overexpression systems and addressed in candidate-gene studies for distinct clinical parameters. In recent years, large cohorts were analyzed in genome-wide association studies (GWAS), where variants are detected as significant in context with specific traits. These studies identified two of the in-depth characterized 18 coding variants in adrenoceptors as repeatedly statistically significant genetic risk factors - p.Arg389Gly in the β<sub>1</sub>- and p.Thr164Ile in the β<sub>2</sub>-adrenoceptor, along with 56 variants in the non-coding regions adjacent to the adrenoceptor gene loci, the functional role of which is largely unknown at present. This chapter summarizes current knowledge on the two coding variants in adrenoceptors that have been consistently validated in GWAS and provides a prospective overview on the numerous non-coding variants more recently attributed to adrenoceptor gene loci.</p>","PeriodicalId":12859,"journal":{"name":"Handbook of experimental pharmacology","volume":" ","pages":"27-54"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Handbook of experimental pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/164_2023_676","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}
引用次数: 0

Abstract

Adrenoceptors are class A G-protein-coupled receptors grouped into three families (α1-, α2-, and β-adrenoceptors), each one including three members. All nine corresponding adrenoceptor genes display genetic variation in their coding and adjacent non-coding genomic region. Coding variants, i.e., nucleotide exchanges within the transcribed and translated receptor sequence, may result in a difference in amino acid sequence thus altering receptor function and signaling. Such variants have been intensely studied in vitro in overexpression systems and addressed in candidate-gene studies for distinct clinical parameters. In recent years, large cohorts were analyzed in genome-wide association studies (GWAS), where variants are detected as significant in context with specific traits. These studies identified two of the in-depth characterized 18 coding variants in adrenoceptors as repeatedly statistically significant genetic risk factors - p.Arg389Gly in the β1- and p.Thr164Ile in the β2-adrenoceptor, along with 56 variants in the non-coding regions adjacent to the adrenoceptor gene loci, the functional role of which is largely unknown at present. This chapter summarizes current knowledge on the two coding variants in adrenoceptors that have been consistently validated in GWAS and provides a prospective overview on the numerous non-coding variants more recently attributed to adrenoceptor gene loci.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
肾上腺素受体的遗传变异。
肾上腺素受体是 A 类 G 蛋白偶联受体,分为三个家族(α1-、α2- 和 β-肾上腺素受体),每个家族包括三个成员。所有九个相应的肾上腺素受体基因在其编码和邻近的非编码基因组区域都显示出遗传变异。编码变异,即转录和翻译受体序列中的核苷酸交换,可能导致氨基酸序列的差异,从而改变受体的功能和信号传导。人们在体外过表达系统中对此类变异进行了深入研究,并在候选基因研究中针对不同的临床参数进行了探讨。近年来,在全基因组关联研究(GWAS)中对大型队列进行了分析,发现了与特定性状相关的重要变异。这些研究发现,肾上腺素受体 18 个编码变异中的两个--β1-肾上腺素受体中的 p.Arg389Gly 和 β2-肾上腺素受体中的 p.Thr164Ile --具有深入特征的变异,以及肾上腺素受体基因位点邻近的非编码区中的 56 个变异,在统计学上多次被认为是重要的遗传风险因素,而这些变异的功能作用目前在很大程度上还不清楚。本章总结了目前关于肾上腺素受体中两个编码变异的知识,这两个变异已在 GWAS 中得到一致验证,并对最近归因于肾上腺素受体基因位点的大量非编码变异进行了前瞻性概述。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Handbook of experimental pharmacology
Handbook of experimental pharmacology Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)
CiteScore
5.20
自引率
0.00%
发文量
54
期刊介绍: The Handbook of Experimental Pharmacology is one of the most authoritative and influential book series in pharmacology. It provides critical and comprehensive discussions of the most significant areas of pharmacological research, written by leading international authorities. Each volume in the series represents the most informative and contemporary account of its subject available, making it an unrivalled reference source.
期刊最新文献
What Is QSP and Why Does It Exist?: A Brief History. Quantitative Systems Pharmacology Modeling in Immuno-Oncology: Hypothesis Testing, Dose Optimization, and Efficacy Prediction. Application of Quantitative Systems Pharmacology Approaches to Support Pediatric Labeling in Rare Diseases. The Use of Natural Products for Preventing Cognitive Decline/Providing Neuroprotection. Natural Products to Promote Vascular Health.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1